In this project, Dr Christopher Cunningham and Dr Adele Moatti at the University of Pittsburgh, USA, are developing a gene therapy as a method to treat hearing loss caused by mutations in the TOMT gene. Project start date: March 2026 Project end date: February 2028 About the project There is an urgent need for safe and effective therapies that restore natural hearing....
✦ Clinical Takeaway ✦
No actionable change — this is an early-stage gene therapy development project with no clinical results.
✦ Why It Matters ✦
TOMT-linked hearing loss is a distinct genetic subtype, and targeted gene therapies for specific mutations represent the frontier of curative audiology research.
✦ Key Points ✦
- 01Drs. Cunningham and Moatti at University of Pittsburgh are developing a TOMT-targeted gene therapy.
- 02Project runs March 2026–February 2028 and is currently in development phase.
- 03TOMT gene mutations affect inner-ear hair cell function, causing hereditary hearing loss.
- 04No human or animal efficacy data reported in this article.
- 05Funded and reported by RNID.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
A gene therapy targeting TOMT gene mutations is being developed to treat hereditary hearing loss.
press releaseunclear